Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients: A Prospective, Multicenter, Randomized, Open-label, Controlled Phase III Study

NCT02011841 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT02011841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02011841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients: A Prospective, Multicenter, Randomized, Open-label, Controlled Phase III Study
Lead sponsor
Seoul National University Hospital
Phase
Phase 3
Overall status
Withdrawn
Start date
January 31, 2014
Completion date
December 31, 2015
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

spontaneous bacterial peritonitis